Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing

Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing

Herpes zoster (HZ) is a painful, unilateral rash which occurs upon reactivation of latent varicella zoster virus due to age-related immunity decline or immuno-suppression. In 2019, the recombinant zoster vaccine (RZV) was the first vaccine to be approved in China for HZ prevention. This study aimed...

Full description

Bibliographic Details
Main Authors: Christa Lee, Ning Jiang, Haiwen Tang, Chiyu Ye, Yanfei Yuan, Desmond Curran
Format: Article
Language:English
Published: Taylor & Francis Group 2021-10-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
herpes zoster
public health impact
vaccination
healthcare resource utilization
china
shingles
postherpetic neuralgia
older adults
Online Access:http://dx.doi.org/10.1080/21645515.2021.1932216

Similar Items

Similar Items